PET-guided radiation for high-risk meningiomas
Part of Brain & nervous system, Cancer clinical trials.
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a grade 3 meningioma (any type) OR a grade 2 meningioma that came back OR a first-time grade 2 meningioma with leftover tumor after surgery.
- If your tumor came back, your doctor can confirm it by a scan or a biopsy.
- You have not had radiation to the brain before.
- You are well enough to be up and about (ECOG score 0-2).
- You are able to have an MRI and a PET scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of radiation (protons) for brain tumors called atypical or anaplastic meningiomas that need radiotherapy. It may help by aiming radiation more precisely while also learning the safest and most effective dose.
This trial uses a special PET scan (DOTATATE) to help plan radiation treatment for meningioma, a type of brain tumor. It aims to make radiation more precise, possibly reducing side effects.
This study uses a special PET scan to see if a protein called PSMA is present on recurrent meningiomas. The results will help plan a future treatment that targets this protein with radioactive medicine.
This study tests a type of focused radiation therapy (called stereotactic radiosurgery) given after surgery for certain meningiomas. The goal is to see if this treatment helps prevent the tumor from coming back, and to check its safety.
This study compares different radiation methods for treating a slow-growing, non-cancerous brain tumor at the base of the skull. It aims to see which approach best protects memory and thinking abilities.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.